SCHEMBL23521925

SCHEMBL23521925

O=C(NCc1ccc(Cl)c(Cl)c1)c1nccnn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ LMNA P02545 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ MAOB P27338 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ HDAC9 Q9UKV0 1/20 0.46
▸ HDAC5 Q9UQL6 1/20 0.46
▸ APEX1 P27695 1/20 0.44
▸ WDR5 P61964 3/20 0.44
▸ CNR1 P21554 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29807696 1.00 TSHR (0.51) TSHRMEN1ALDH1A1KMT2AHPGD
SCHEMBL23521747 0.85 CYP2C19 (0.58) TSHRMEN1ALDH1A1KMT2AHPGD
SCHEMBL29808056 0.85 CYP2C19 (0.58) TSHRMEN1ALDH1A1KMT2AHPGD
SCHEMBL29807934 0.83 NPC1 (0.56) MEN1KMT2ALMNAMAOBHDAC1
SCHEMBL23521941 0.83 NPC1 (0.56) MEN1KMT2ALMNAMAOBHDAC1
SCHEMBL23521860 0.80 KMT2A (0.61) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL29819690 0.80 KMT2A (0.61) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL28931232 0.80 KMT2A (0.47) ALDH1A1KMT2AHPGDSMN1; SMN2MAOB
SCHEMBL28931229 0.79 L3MBTL1 (0.56) KMT2ALMNASMN1; SMN2
SCHEMBL29536120 0.79 L3MBTL1 (0.56) KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4104902-B1 COMPOUNDS AND MEDICAMENTS USING SAME IRIMAJIRI THERAPEUTICS INC (JP) 2026-05-27 — — EP disclosed
US-11780841-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same IRIMAJIRI THERAPEUTICS INC. (JP) 2023-10-10 — — US disclosed
EP-3838901-B1 COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES IRIMAJIRI THERAPEUTICS INC (JP) 2023-09-27 — — EP disclosed
EP-4104902-A1 COMPOUND AND DRUG CONTAINING SAME Oita University Institute of Advanced Medicine, Inc. (JP) 2022-12-21 — — EP disclosed
CN-115260193-A Compounds and methods for treating rabies 株式会社大分大学先端医学研究所 2022-11-01 — — CN disclosed
CN-115052661-A Compound and drug using the same 株式会社大分大学先端医学研究所 2022-09-13 — — CN disclosed
CN-112839944-B Compounds and methods for treating rabies 株式会社大分大学先端医学研究所 2022-08-05 — — CN disclosed
US-20220194942-A1 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME IRIMAJIRI THERAPEUTICS INC. (JP) 2022-06-23 — — US disclosed
US-11292794-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC. (JP) 2022-04-05 — — US disclosed
EP-3838901-A1 COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES Oita University Institute of Advanced Medicine, Inc. (JP) 2021-06-23 — — EP disclosed
CN-112839944-A Compounds and methods for treating rabies 株式会社大分大学先端医学研究所 2021-05-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11292794-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same AVPR1B, F12, SDHB TSHR 3512/4885MEN1 203/4885ALDH1A1 2885/4885
US-11780841-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same AVPR1B, AVPR2, F12 TSHR 3098/4885MEN1 248/4885ALDH1A1 3237/4885
US-20220194942-A1 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME AVPR1B, AVPR2, F12 TSHR 3098/4885MEN1 248/4885ALDH1A1 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback